Hewang Pharmaceuticals and GSK reached an licensing agreement for the HMPL-A830. According to a research report published by Citigroup, GSK's approval verified the ATTC platform concept, and the transaction was reached earlier than expected by the bank. In addition, Citi expects HMPL-A251 and HMPL-A580 to be administered to patients for the first time from the end of this year to the beginning of next year. At that time, more human data will further validate the ATTC platform. The bank raised Hewong Pharmaceutical's revenue forecast for 2026-28 by 27%, 26% and 14%, raised earnings estimates to $0.08, 0.09 and $0.13 per share, and raised the target price from HK$36 to HK$39, maintaining the “buy/high risk” rating.

Hewang Pharmaceuticals and GSK reached an licensing agreement for the HMPL-A830. According to a research report published by Citigroup, GSK's approval verified the ATTC platform concept, and the transaction was reached earlier than expected by the bank. In addition, Citi expects HMPL-A251 and HMPL-A580 to be administered to patients for the first time from the end of this year to the beginning of next year. At that time, more human data will further validate the ATTC platform. The bank raised Hewang Pharmaceutical's revenue forecast for 2026-28 by 27%, 26% and 14%, raised earnings estimates to $0.08, 0.09 and $0.13 per share, and raised the target price from HK$36 to HK$39, maintaining the “buy/high risk” rating.